# Unlocking Value: 10 Stocks to Watch Now! Newsy: Value Investor Weekly Published: 2026-01-15T12:46:00.519Z Source: https://newsyai.com/edition/a04c087e-d55a-40bb-be42-2bf11143bf40 Archive: https://newsyai.com/newsy/5bbbadf7-1e6d-4c85-a79b-15b39036f33d.md --- # Value Radar: 10 Fresh Ideas + Full Valuation Deep‑Dive on Bristol Myers Squibb (BMY) Date: January 15, 2026 (United States) Market backdrop: The 10‑year U.S. Treasury yield sits around 4.15%–4.19% this week, a useful anchor for discount rates in equity valuation. ([federalreserve.gov](https://www.federalreserve.gov/releases/h15/?utm_source=openai)) --- ## 1) 10 Value‑Based Candidates To Research Now What “value” means here: durable cash flows, reasonable leverage, and shares trading below a conservative appraisal of intrinsic value, with identifiable catalysts over the next 12–24 months. 1) Bristol Myers Squibb (BMY) — pipeline‑led transition through loss‑of‑exclusivity; fresh assets (e.g., Cobenfy/KarXT) and lifecycle work on Opdivo; 2025 non‑GAAP EPS guidance raised to $6.70–$7.00. Deep‑dive below. ([investors.bms.com](https://investors.bms.com/iframes/press-releases/press-release-details/2025/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results-for-2025/default.aspx?utm_source=openai)) 2) FedEx (FDX) — cost‑takeout delivering; DRIVE savings achieved in FY25; raised FY26 outlook; Freight spin‑off targeted June 1, 2026. ([investors.fedex.com](https://investors.fedex.com/news-and-events/investor-news/investor-news-details/2025/FedEx-Reports-Fourth-Quarter-Diluted-EPS-of-6-88-and-Adjusted-Diluted-EPS-of-6-07/default.aspx?utm_source=openai)) 3) State Street (STT) — fee engine with improving operating leverage; Q3‑25 EPS +23% y/y, strong capital ratios. ([nasdaq.com](https://www.nasdaq.com/articles/state-street-q3-earnings-beat-y-y-growth-fee-revenues?utm_source=openai)) 4) Nucor (NUE) — tariff‑aided steel pricing, mills segment strength; cyclical but disciplined capex. ([reuters.com](https://www.reuters.com/markets/commodities/us-steelmaker-nucor-tops-quarterly-estimates-higher-spot-prices-2025-04-28/?utm_source=openai)) 5) Gilead (GILD) — resilient HIV franchise; 2025 product‑sales outlook raised; dividend discipline. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-quarterly-results-beat-estimates-2025-02-11/?utm_source=openai)) 6) Amgen (AMGN) — Horizon integration, manufacturing expansion; diverse biologics pipeline. ([amgen.com](https://www.amgen.com/newsroom/press-releases/2025/09/amgen-announces-650m-expansion-of-us-manufacturing-creating-hundreds-of-new-jobs?utm_source=openai)) 7) Keurig Dr Pepper (KDP) — steady mid‑/high‑single‑digit algorithm; 2025 outlook raised; strategic coffee M&A optionality. ([keurigdrpepper.com](https://www.keurigdrpepper.com/keurig-dr-pepper-reports-q3-2025-results-raises-full-year-net-sales-outlook-and-reaffirms-eps-guidance-for-2025-2/?utm_source=openai)) 8) Lowe’s (LOW) — cash‑return flywheel and share shrink; leverage to repair/remodel normalization (monitor housing). [Company IR/press.] 9) Cummins (CMI) — dependable mid‑cycle cash flows; energy transition optionality via Accelera. [Company IR/press.] 10) WestRock/Smurfit WestRock (post‑deal) — scale, synergy, and box demand normalization tailwinds. ([ir.westrock.com](https://ir.westrock.com/press-releases/press-release-details/2023/Statement-re-Smurfit-Kappa-and-WestRock-Announce-Transaction-to-Create-a-Global-Leader-in-Sustainable-Packaging/default.aspx?utm_source=openai)) --- ## 2) Deep Dive: Bristol Myers Squibb (BMY) — Transitioning Through the Cliff ### 2.1 What BMY is today - Business mix: oncology/immunology/hematology mainstays (Opdivo, Eliquis alliance with Pfizer), plus newer assets from acquisitions (Karuna/KarXT; Mirati; RayzeBio). 2024 revenue was $48.3B; operating cash flow $15.2B; year‑end cash $10.3B vs. total debt $49.4B (principal). ([sec.gov](https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/bmy-20241231.htm)) - 2025 guide (most recent company update): revenue raised to ~$45.8–$46.8B in April 2025 and further to $47.5–$48.0B after Q3‑25; non‑GAAP EPS raised to $6.70–$7.00. ([investors.bms.com](https://investors.bms.com/iframes/press-releases/press-release-details/2025/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results-for-2025/default.aspx?utm_source=openai)) - Cost actions: total program expanded to $3.5B savings through 2027. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-sees-sharper-2025-revenue-drop-after-better-than-forecast-q4-2025-02-06/?utm_source=openai)) Key recent developments we will model around: - Eliquis U.S. “maximum fair price” under IRA for Medicare starting in 2026, and U.S. generic entry expected April 1, 2028 per court‑upheld patents. EU LOE in 2H26 in key markets. ([bms.com](https://www.bms.com/investor-statement-on-eliquis-revenue-under-ira.html?utm_source=openai)) - Opdivo lifecycle: subcutaneous Opdivo Qvantig approved in Dec‑2024, an important share‑defense tool as core IV patents roll off later this decade; priority‑review sBLA for Hodgkin lymphoma has an April 8, 2026 PDUFA. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-injectable-form-bristol-myers-opdivo-2024-12-27/?utm_source=openai)) - Karuna (KarXT; marketed as Cobenfy for schizophrenia in 2025): acquisition closed March 2024; launch in progress and part of “growth portfolio” momentum. ([businesswire.com](https://www.businesswire.com/news/home/20240318509649/en/Bristol-Myers-Squibb-Completes-Acquisition-of-PureTechs-Founded-Entity-Karuna-Therapeutics-for-%2414-Billion?utm_source=openai)) Why it screens as value now - Shares price in prolonged LOE fear and leverage from 2024‑era dealmaking, leaving BMY on a single‑digit forward P/E versus large‑cap pharma peers in the teens. The company’s own guidance and cash generation anchor downside provided execution on the growth portfolio continues. ([investors.bms.com](https://investors.bms.com/iframes/press-releases/press-release-details/2025/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results-for-2025/default.aspx?utm_source=openai)) --- ### 2.2 Roadmap, end‑market context, and what’s changing - Legacy pressure vs. growth offset • Management flagged 2025 legacy portfolio revenue declines (Revlimid, Pomalyst, Sprycel, Abraxane), partly offset by growth brands; that pattern largely played out through 2025 with reiterated and then raised full‑year guidance. ([news.bms.com](https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2024/default.aspx?utm_source=openai)) • Eliquis: Medicare price cuts begin 2026; EU generics in 2H26; U.S. generics in 2028 per litigation outcomes—this is the single biggest near‑term swing factor. ([bms.com](https://www.bms.com/investor-statement-on-eliquis-revenue-under-ira.html?utm_source=openai)) - Opdivo defense and expansion • The subcutaneous formulation (Opdivo Qvantig) meaningfully reduces chair time and can slow erosion as biosimilar risks approach later this decade. Additional first‑line indications (e.g., cHL) are under priority review. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-injectable-form-bristol-myers-opdivo-2024-12-27/?utm_source=openai)) - New launch engine • Cobenfy (KarXT) launched; multiple label expansions are in development, but management still has to prove durable uptake beyond early demand. ([sec.gov](https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/bmy-20241231.htm)) --- ## 3) Ground‑Up Valuation: FCFF DCF + Comparable Checks We build a conservative, cross‑checked FCFF model from company‑reported baselines, layering in the IRA and LOE timing. ### 3.1 Core inputs (with corroboration) - Starting financials (base year = 2024 actuals) • Revenue $48.3B; operating cash flow $15.2B; capex ~$1.25B; cash $10.3B; total debt (principal) ~$48.9B; net debt ≈ $38.5B. ([sec.gov](https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/bmy-20241231.htm)) - 2025 revenue/EPS “frame” for near‑term normalization • Latest 2025 guide (after Q3‑25): revenue $47.5–$48.0B; non‑GAAP EPS $6.40–$6.60 (earlier), then raised to $6.70–$7.00 by April update; we anchor to the higher EPS band as the latest management view into 2026. ([tipranks.com](https://www.tipranks.com/news/company-announcements/bristol-myers-squibb-reports-q3-2025-financial-results?utm_source=openai)) - Eliquis trajectory assumptions (explicit) • 2026–2027 U.S. Medicare “maximum fair price” lowers the Medicare unit value; company’s investor statement frames 2026–2027 Eliquis revenue ranges of $10.5–$12.5B WW in 2026 and $8.5–$11.0B in 2027; U.S. generics from Apr 1, 2028. We embed a down‑shift in 2026–2027 and a larger step‑down in 2028. ([bms.com](https://www.bms.com/investor-statement-on-eliquis-revenue-under-ira.html?utm_source=openai)) - Opdivo and growth portfolio • Assume mid‑single‑digit growth for Opdivo through 2027 aided by Qvantig and new indications, tapering thereafter; growth portfolio (Reblozyl, Camzyos, Breyanzi, Cobenfy, etc.) supports total company stability into 2027. (Anchored by 2025 “growth portfolio” updates.) ([barrons.com](https://www.barrons.com/articles/bristol-myers-squibb-earnings-stock-price-a0bddbf7?utm_source=openai)) - Margins and taxes • 2025 gross margin guide ~72%; operating expenses ~$16B; tax rate ~18%. We model a non‑GAAP operating margin in the mid‑30s, reflecting historical profitability adjusted for higher amortization/deal costs on GAAP. ([news.bms.com](https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2024/default.aspx?utm_source=openai)) - Capex and working capital • Capex held at ~$1.3–1.5B; working‑capital changes net to modest over the cycle (consistent with 2024 cash‑flow cadence). ([sec.gov](https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/bmy-20241231.htm)) - Discount rate (WACC) • Risk‑free set to the 10‑yr at ~4.15%–4.19% (Jan 2026). Large‑cap pharma beta historically ~0.6–0.7; equity risk premium 5.0%; after‑tax cost of debt ~4.5–5.0% given BMY’s mix. We use WACC = 8.0% (base), 7.0% (bull), 9.0% (bear). ([federalreserve.gov](https://www.federalreserve.gov/releases/h15/?utm_source=openai)) ### 3.2 FCFF path (explicit years 2026–2030; $ billions) Method: FCFF anchored to cash generation (CFO – capex, adjusted for one‑offs) and cross‑checked vs. revenue/margin logic above. - Base case FCFF: • 2026: 12.5 (IRA drag on Eliquis; growth brands offset) • 2027: 12.7 (growth brands + Opdivo mix) • 2028: 11.0 (U.S. Eliquis generics from Apr 1) • 2029: 12.0 (growth assets scale) • 2030: 12.8 (further ramp/efficiency) Terminal growth g = 1.5% (mature pharma). Discount at 8.0%. - Present value math (summarized) • PV of 2026–2030 FCFF ≈ $48.7B; PV of terminal value ≈ $136.1B → Enterprise value ≈ $184.8B. • Less net debt ≈ $38.5B (12/31/2024), equity value ≈ $146B. With ~2.04B diluted shares, intrinsic ≈ $72/share. - Sensitivities • Bear (WACC 9%, g 1%; deeper 2028 step‑down): $46/share. • Base (as above): ~$72/share. • Bull (WACC 7%, g 2%; stronger growth portfolio and Opdivo/cHL win flow‑through): ~$115/share. Why these levels are reasonable: the explicit drop in 2028 is tied directly to the company’s own LOE/IRA disclosures, while the recovery assumes continued execution in the “growth portfolio” where BMY’s quarterly prints have shown mid‑teens contribution and repeated guide raises during 2025. ([bms.com](https://www.bms.com/investor-statement-on-eliquis-revenue-under-ira.html?utm_source=openai)) ### 3.3 Comparable checks (sanity) - Forward P/E: Using BMY’s 2025 non‑GAAP EPS midpoint ($6.85) and a ~$45 stock price implies ~6.6x—well below many large‑cap pharma peers (e.g., ABBV ~16x; GILD roughly low‑teens on 2025 EPS). This is consistent with the market pricing a steep, prolonged LOE hole. ([news.bms.com](https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2024/default.aspx?utm_source=openai)) - Balance sheet: Net debt ≈ $38.5B (12/31/24) is meaningful but supported by ~$15B annual operating cash flow, giving flexibility for debt tenders and bolt‑ons. ([sec.gov](https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/bmy-20241231.htm)) --- ## 4) What the market may be missing - Subcutaneous Opdivo is not a panacea but does improve patient/provider convenience; it can slow share erosion and support extensions as biosimilar risk approaches. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-injectable-form-bristol-myers-opdivo-2024-12-27/?utm_source=openai)) - The company has repeatedly adjusted 2025 guidance upward as the “growth portfolio” contribution accelerates; that underpins our base‑case margin and FCFF resilience pre‑2028. ([investors.bms.com](https://investors.bms.com/iframes/press-releases/press-release-details/2025/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results-for-2025/default.aspx?utm_source=openai)) - Eliquis revenue contours are unusually transparent (IRA MFP table + LOE dates). Models that still assume a cliff in 2026 for the U.S. likely over‑penalize near‑term cash flows. ([bms.com](https://www.bms.com/investor-statement-on-eliquis-revenue-under-ira.html?utm_source=openai)) --- ## 5) Risks - Execution on growth brands (Cobenfy, Reblozyl, Camzyos, Breyanzi) and continued Opdivo label wins; weaker uptake would compress our FCFF path. ([barrons.com](https://www.barrons.com/articles/bristol-myers-squibb-earnings-stock-price-a0bddbf7?utm_source=openai)) - Policy and pricing (IRA implementation details, further reforms). ([bms.com](https://www.bms.com/investor-statement-on-eliquis-revenue-under-ira.html?utm_source=openai)) - Litigation/LOE timing variance outside the U.S. for Eliquis; competitive PD‑1 dynamics in immuno‑oncology. ([bms.com](https://www.bms.com/investor-statement-on-eliquis-revenue-under-ira.html?utm_source=openai)) --- ## 6) Bottom Line and Price Map - Intrinsic value range (DCF): $46–$115 per share, Base ≈ $72. - Investment view: For value investors, BMY offers an attractive, cash‑backed setup if you can tolerate 2028’s U.S. Eliquis step‑down. Accumulate on weakness below ~$55 with a three‑ to five‑year horizon, expect elevated volatility around 2026–2028 policy/patent milestones. - What to watch next 2–4 quarters: growth‑portfolio quarterly cadence; Opdivo sBLA (cHL) by April 8, 2026; any new IRA implementation updates; capital‑structure moves (debt tenders/buybacks). ([news.bms.com](https://news.bms.com/news/corporate-financial/2025/U-S--Food-and-Drug-Administration-FDA-Grants-Priority-Review-to-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-Plus-Chemotherapy-Combination-for-Classical-Hodgkin-Lymphoma/default.aspx?utm_source=openai)) --- ## 7) Valuation “Audit Trail” — Key Sources and Cross‑Checks - 2024 Form 10‑K (financials, cash flow, debt, product disclosures). ([sec.gov](https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/bmy-20241231.htm)) - 2024 results and initial 2025 guidance (72% GM, ~$16B opex, tax ~18%). ([news.bms.com](https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2024/default.aspx?utm_source=openai)) - Q1‑2025 guidance raise; latest revenue/EPS bands. ([investors.bms.com](https://investors.bms.com/iframes/press-releases/press-release-details/2025/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results-for-2025/default.aspx?utm_source=openai)) - Q3‑2025 results and outlook update. ([tipranks.com](https://www.tipranks.com/news/company-announcements/bristol-myers-squibb-reports-q3-2025-financial-results?utm_source=openai)) - Eliquis IRA “maximum fair price” table and U.S. LOE date (Apr 1, 2028); legal background. ([bms.com](https://www.bms.com/investor-statement-on-eliquis-revenue-under-ira.html?utm_source=openai)) - Opdivo Qvantig (subcutaneous) FDA approval; priority review for cHL combination. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-injectable-form-bristol-myers-opdivo-2024-12-27/?utm_source=openai)) - Karuna acquisition close and integration into the portfolio. ([businesswire.com](https://www.businesswire.com/news/home/20240318509649/en/Bristol-Myers-Squibb-Completes-Acquisition-of-PureTechs-Founded-Entity-Karuna-Therapeutics-for-%2414-Billion?utm_source=openai)) - Risk‑free rate (H.15 daily). ([federalreserve.gov](https://www.federalreserve.gov/releases/h15/?utm_source=openai)) --- ## 8) One‑liners on today’s other nine ideas (sources) - FedEx: FY25 DRIVE savings met; FY26 guide raised; spin‑off of FedEx Freight targeted for June 1, 2026. ([investors.fedex.com](https://investors.fedex.com/news-and-events/investor-news/investor-news-details/2025/FedEx-Reports-Fourth-Quarter-Diluted-EPS-of-6-88-and-Adjusted-Diluted-EPS-of-6-07/default.aspx?utm_source=openai)) - State Street: Q3‑25 EPS beat; fee growth strong; CET1 ~11.3%. ([nasdaq.com](https://www.nasdaq.com/articles/state-street-q3-earnings-beat-y-y-growth-fee-revenues?utm_source=openai)) - Nucor: Q1‑25 beat on mills strength; tariff backdrop supportive. ([reuters.com](https://www.reuters.com/markets/commodities/us-steelmaker-nucor-tops-quarterly-estimates-higher-spot-prices-2025-04-28/?utm_source=openai)) - Gilead: raised 2025 outlook; HIV strength offsets other pressures. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-quarterly-results-beat-estimates-2025-02-11/?utm_source=openai)) - Amgen: U.S. manufacturing expansion; Horizon integration watch‑item. ([amgen.com](https://www.amgen.com/newsroom/press-releases/2025/09/amgen-announces-650m-expansion-of-us-manufacturing-creating-hundreds-of-new-jobs?utm_source=openai)) - Keurig Dr Pepper: 2025 net‑sales outlook raised; steady EPS guide; potential coffee platform dealmaking. ([keurigdrpepper.com](https://www.keurigdrpepper.com/keurig-dr-pepper-reports-q3-2025-results-raises-full-year-net-sales-outlook-and-reaffirms-eps-guidance-for-2025-2/?utm_source=openai)) - Lowe’s: capital‑returns compounding; monitor housing/DIY elasticity. [Company IR/press.] - Cummins: durable engine cash flows; energy transition via Accelera. [Company IR/press.] - WestRock/Smurfit WestRock: combination creates global packaging scale; synergy capture is key. ([ir.westrock.com](https://ir.westrock.com/press-releases/press-release-details/2023/Statement-re-Smurfit-Kappa-and-WestRock-Announce-Transaction-to-Create-a-Global-Leader-in-Sustainable-Packaging/default.aspx?utm_source=openai)) --- Disclaimer: This independent analysis is for educational purposes only and is not investment advice. Do your own research and consider your objectives and risk tolerance.